News & Media

Take a look inside our world

Press Releases

Teva to Present at the Jefferies London Healthcare Conference

Teva to Present at the Jefferies London Healthcare Conference

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance a...

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and In

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Reveal...

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing D

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demon...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrat

Teva Statement on European Commission Decision; Company to Appeal

Teva Statement on European Commission Decision; Company to Appeal

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-ae...

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn),

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candida...

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide ac...

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on Novembe...

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6,
View all press releases
Previous
Next

Contacts for Media Inquiries

Kelley Dougherty

North America

+1-973-658-0237
Kelley.Dougherty@tevapharm.com

Eden Klein

Israel & Corporate

+972-3-9062645
Eden.Klein@teva.co.il

Fiona Cohen

Europe

fiona.cohen@tevaeu.com

Teva Media Assets

These proprietary media assets are available for download and are intended for non-commercial media use and research only.

Download Logo Download Teva B-Roll

Feature stories

All Access to Medicine Biologics Biosimilars Caregivers Environment Generic Medicines Global Operations Immunology Innovation Leadership Inclusion & Diversity Neuroscience Our People Patient Focus Quality Research & Development Respiratory Sustainability Wellbeing Working at Teva

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

3 Trends I’m Watching in Pharmaceutical Marketing and Digital

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Spreading HOPE: Teva’s Work to Improve Global Access to Medicine

Living With an Invisible Disability: What We All Need to Know

Living With an Invisible Disability: What We All Need to Know

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

Treating the Untreatable: Harnessing Biological Processes to Fight Disease

A Passport to Career Development: A Journey with Teva's R&D Teams

A Passport to Career Development: A Journey with Teva's R&D Teams

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

The Neuroscience of Inclusion and Diversity: Unlocking High-Impact Team Performance

Migraine at Work: How it Impacts Us All

Migraine at Work: How it Impacts Us All

What are Biologics and Biosimilars?

What are Biologics and Biosimilars?

Medical Specialists We All Need but Never See: Safety Physicians

Medical Specialists We All Need but Never See: Safety Physicians

3 Trends I’m Watching in Sustainability

3 Trends I’m Watching in Sustainability
View all stories

Connect with us on social media

Follow us on Facebook

Go to facebook.com

Follow us on Linkedin

Go to linkedin.com

Follow us on Twitter

Go to twitter.com

View our Social Media Guidelines

Learn more